Frédérique Caillot

First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial

P. Joly, Maud Maho‐Vaillant, C. Prost‐Squarcioni et al. · The Lancet · 2017 · 596 citations

Medicine, Internal Medicine, Pharmacotherapy +9

Long-Term Remissions of Severe Pemphigus After Rituximab Therapy Are Associated with Prolonged Failure of Desmoglein B Cell Response

Natacha Colliou, D Picard, Frédérique Caillot et al. · Science Translational Medicine · 2013 · 243 citations

Life Sciences, Immunology, Pharmacotherapy +17

Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid‐sparing effect

D.M. Chen, Adefowope Odueyungbo, Eva Csinady et al. · British Journal of Dermatology · 2019 · 95 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +14

B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid

Nicolas Berkani, P. Joly, Marie-Laure Golinski et al. · Scientific Reports · 2019 · 36 citations · Full text

Life Sciences, Dermatology, Immunology +17

Rituximab and Corticosteroid Effect on Desmoglein-Specific B Cells and Desmoglein-Specific T Follicular Helper Cells in Pemphigus

Maud Maho‐Vaillant, Corine Pérals, Marie-Laure Golinski et al. · Journal of Investigative Dermatology · 2021 · 33 citations · Full text

Life Sciences, Immunology, Pathology +16